Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

Despite FDA approvals of exa-cel (Casgevy) for treating TDT and SCD, CRISPR's stock price is down more than 32% in the past six months. While CRISPR will split exa-cel profits with Vertex ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In ... that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter ...

CRISPR Therapeutics AG (CRSP) stock price is 41.21 and CRISPR Therapeutics AG (CRSP) 10-day simple moving average is 41.52. CRISPR Therapeutics AG (CRSP) stock price is 41.21 and CRISPR ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...

Crispr Therapeutics (NASDAQ: CRSP) is a fascinating growth stock that I’ve been watching for a few years now. In early 2021 it soared to a ridiculous $200, despite the gene-editing biotech having no ...